Bristol Myers Squibb Company (NYSE:BMY) Stock Has Consensus Target Price of $67.06

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $67.06.

BMY has been the topic of a number of research reports. Piper Sandler reiterated an “overweight” rating and issued a $82.00 price target (up from $75.00) on shares of Bristol Myers Squibb in a report on Wednesday, September 16th. Royal Bank Of Canada raised their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb selected Onco360 as a restricted specialty pharmacy for ZENBEXUS (iberdomide), enabling specialty dispensing and clinical support as the newly approved multiple myeloma treatment begins its commercial rollout. The launch could provide a new revenue stream in an underserved patient population. Bristol Myers Squibb Adds Restricted Pharmacy Path for New Myeloma Drug
• Positive Sentiment: Recent traction from newer medicines is helping offset declines from mature products, improving BMY’s revenue mix and supporting the investment case that its growth portfolio can soften upcoming patent losses. Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
• Positive Sentiment: Completion of a Phase 1 lung-cancer combination study adds incremental support to Bristol Myers Squibb’s immuno-oncology pipeline, though the early-stage update does not yet establish clinical or commercial success. BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline
• Positive Sentiment: Zacks added BMY to its Rank #1 Strong Buy list and its Strong Buy income-stock list, potentially improving sentiment among momentum and dividend-focused investors. New Strong Buy Stocks for September 24th
• Neutral Sentiment: Investment coverage highlights BMY’s specialized drug portfolio, strong free cash flow and generous dividend, but also notes the company’s exposure to patent expirations and the need for its pipeline to deliver the next phase of growth. Bristol Myers Squibb vs. Pfizer

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $61.54 on Friday. The stock has a 50-day moving average price of $64.44 and a 200 day moving average price of $60.15. The stock has a market capitalization of $125.71 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently modified their holdings of BMY. KCM Investment Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 174 shares during the last quarter. Sandy Cove Advisors LLC increased its holdings in Bristol Myers Squibb by 4.7% during the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 176 shares during the last quarter. Investment Research Partners LLC raised its position in Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 179 shares during the period. REAP Financial Group LLC boosted its stake in Bristol Myers Squibb by 26.1% in the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 182 shares during the last quarter. Finally, Key Financial Inc grew its position in shares of Bristol Myers Squibb by 2.4% during the 1st quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 183 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.